Gina R. Consylman
Independent DirectorMs. Gina R. Consylman, C.P.A., serves as Chief Financial Officer of Vedere Bio II, Inc. since April 2022. She served as Chief Financial Officer at bluebird bio, Inc. since 2021 until April 03, 2022 and served as its Treasurer until April 03, 2022. She joined bluebird in August 2021, overseeing finance, tax, accounting, treasury, insurance and investor relations and served as its Principal Accounting Officer. She served as Director of Verastem, Inc. since October 18, 2018 until 2021. She is an Independent Director of Assembly Biosciences, Inc. since October 2020. She had been Senior Vice President of Ironwood Pharmaceuticals, Inc. since November 28, 2017 until July 02, 2021 and had been its Principal Accounting Officer since February 19, 2021 until July 02, 2021. Since April 2022, Ms. Consylman has served as Chief Financial Officer of Vedere Bio II, Inc. She served as a Chief Financial Officer and Treasurer at Ironwood Pharmaceuticals, Inc until July 02, 2021. Ms. Consylman served as Chief Accounting Officer of Ironwood Pharmaceuticals, Inc. from June 2014 to December 2, 2017 and also served as its Chief Financial Officer. Ms. Consylman served as Interim Chief Financial Officer and Vice President of Finance at Ironwood Pharmaceuticals, Inc. since September 13, 2017 and August 2015 respectively until November 28, 2017. Ms. Consylman served as Corporate Controller of Ironwood Pharmaceuticals, Inc. since June 2014 to July 2015. She served as Vice President and Corporate Controller of Analogic Corporation from February 27, 2012 to June 2014 and served as its Principal Accounting Officer from March 15, 2012 to June 13, 2014. Ms. Consylman has held a number of key financial leadership roles in high growth, global healthcare and technology companies. Since February 2011, Ms. Consylman has served as a Senior Director, Corporate Accounting at Biogen Idec Inc., prior to which she served as Director of Corporate Accounting from November 2009 to February 2011. While at Biogen Idec, Ms. Consylman was responsible for the accounting teams for the Corporate and U.S. Commercial business units. From September 2001 to November 2009, she served in various finance and accounting roles, including Corporate Controller, with Varian Semiconductor Equipment Associates, Inc. Varian Semiconductor is a global supplier of ion implantation equipment used in the fabrication of semiconductor chips. From March 1998 to September 2001, Ms. Consylman was Director of Corporate Accounting at Rowecom Inc. Prior to joining Rowecom, she held audit positions with PricewaterhouseCoopers, LLP and Ernst & Young, LLP. She is Interim Head of Strategy and Head of Portfolio and Analytics at Takeda Pharmaceutical Company Limited. Ms. Consylman, a Certified Public Accountant, began her career in public accounting at Ernst & Young LLP and holds a Bachelor of Science degree in Accounting from Johnson & Wales University and a Master's of Science degree in Taxation from Bentley University.
Positions
- Company NameAssembly Biosciences, Inc.Stock CodeASMBPositionIndependent DirectorColleagues
- JAJason A. OkazakiCEO, President & Director
- AEAnthony E. AltigIndependent Chairman
- WEWilliam E. DelaneyChief Scientific Officer
- AGAnuj GaggarChief Medical Officer
- JMJeanette M. BjorkquistPrincipal Financial Officer, Executive Director of Accounting & Treasury
- SRShannon RyanSenior Vice President of Investor Relations, Corporate Affairs & Alliance Management
- SMSusan M. MahonyIndependent Director
- LRLisa R. Johnson-PrattIndependent Director
